DNA-transfer approaches in treatment of chronic inflammatory joint disease

Journal of Long-Term Effects of Medical Implants

Volumn 12, Issue 2, 2002, Pages 71-84

  McDaniel, D Olga ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Cell mediated transport; CIJD; Gene therapy; Rheumatoid arthritis

Indexed keywords

DNA; JOINTS (ANATOMY); MORPHOLOGY; TISSUE;

PAIN CONTROL;

GENETIC ENGINEERING;

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 4; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CHRONIC ARTHRITIS; DEFORMITY; DISABILITY; DNA TRANSFER; DOSE RESPONSE; DRUG EFFICACY; GENE THERAPY; JOINT INJURY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PAIN; RAT; REVIEW; RHEUMATOID ARTHRITIS; TECHNIQUE; VIRAL GENE DELIVERY SYSTEM;

EID: 0036624013     PISSN: 10506934     EISSN: None     Source Type: Journal    
DOI: 10.1615/jlongtermeffmedimplants.v12.i2.30     Document Type: Review

References (77)

1. Gay S, Gay RE, Koopman WJ. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: Two cellular mechanisms explain joint destruction. Ann Rheum Dis 1993; 52:S39-S47.
2. Winchester R. The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 1994; 56:389-466.
3. Harris EB Jr. Rheumatoid arthritis: Pathophysiology and implications for therapy. N Engl J Med 1990; 322:1277-1289.
4. Ali H, Haribabu B, Richardson RM, Snyderman R. Mechanisms of inflammation and leukocyte activation. Med Clin North Am 1997; 81:1-7.
5. Goronzy J, Weyand CM, Fathman CG. Shared T-cell recognition sites on human histocompatibility antigen class II molecules of patients with seropositive rheumatoid arthritis. J Clin Invest 1986; 77:1042-1049.
6. Nepom GT, Hensen JA, Nepom BS. The molecular basis for HLA class II association with rheumatoid arthritis. J Clin Immunol 1987; 7:1-7.
7. Reveille JD. The genetic contribution to the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol 1998; 10:187-200.
8. Weyand CM, McCarthy TG, Goronzy JJ. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest 1995; 95:2120-2126.
9. McDaniel DO, Alarcón GC, Parks PW, Reveille JD. Most African-American patients with rheumatoid arthritis do not have the rheumatoid antigenic determinant (epitope). Ann Int Med 1995; 123:181-187.
10. Teller K, Budhai L, Zhang M, Haramati N, Keiser HD, Davidson A. HLA DRB1 and DQB1 typing of Hispanic-American patients with rheumatoid arthritis: The 'shared epitope' hypothesis may not apply. J Rheumatol 1996; 23:1363-1368.
11. Gregerson PK, Silver J, Winchester RJ. The shared epitope hypothesis - An approach to understanding the molecular genetics of rheumatoid arthritis susceptibility. Arthritis Rheum 1987; 30:1205-1213.
12. McDonagh JE, Dunn A, Ollier WE, Walker DJ. Compound heterozygosity for the shared epitope and the risk and severity of rheumatoid arthritis in extended pedigrees. Br J Rheumatol 1997; 36:322-327.
13. Albani S, Carson DA. A multi-step molecular mimicry hypothesis for the pathogenesis of rheumatoid arthritis. Immunol Today 1996; 17:466-470.
14. Auger I, Escola JM, Gorvel JP, Roudier J. HLA-DR4 and HLA-DR10 motifs that carry susceptibility to rheumatoid arthritis bind 70-KD heat shock proteins. Nat Med 1996; 2:306-310.
15. Zanelli E, Krco CJ, David CS. Critical residues on HLA-DRB1*0402 HV3 peptide for HLA-DQ8-restricted immunogenicity. J Immunol 1997; 158:3545-3551.
16. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, editors. Textbook of Rheumatology. 5th Ed. Philadelphia, PA: WB Sanders, 1997: 851-897.
17. John S, Myerscough A, Marlow A, Hajeer A, Silman A, Ollier W, Worthington J. Linkage of cytokine genes to rheumatoid arthritis: Evidence of genetic heterogeneity. Ann Rheum Dis 1998; 57:361-365.
18. Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: Implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992; 31:653-661.
19. Barnes PJ, Karin M. Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-1071.
20. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, Mapp, PI, Morris CJ, Blake DR, Kaltschmidt C, Baeuerle PA. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum 1996; 39:583-591.
21. Miyazawa K, Mori A, Yamamoto K, Okudaira H. Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: Spontaneous activation of NF-κB and CBFI. Am J Pathol 1998; 152:793-803.
22. Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishioka K. Activation of transcription factor NF-κB in human synovial cells in response to tumor necrosis factor α. Arthritis Rheum 1996; 39:197-203.
23. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kB transcription factor. Mol Cell Biol 1990; 10:2327-2334.
24. Vincenti MP, Coon CI, Brinckerhoff CE. Nuclear factor-κB/p50 activates an element in the distal matrix metaloproteinase 1 promotor in interleukine-1beta-stimulated synovial fibroblasts. Arthritis Rheum 1998; 41:1987-1994.
25. Tomita T, Takano H, Tomita N, Morishita M, Kaneko K, Shi K, Takahi K, Nakase T, Kaneda Y, Yoshikawa H, Ochi T. Transcription factor decoy for NF-κB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology 2000; 39:749-757.
26. Moreland LW, Heck LW, Koopman WJ. Biological agents for treating rheumatoid arthritis: Concepts and progress. Arthritis Rheum 1997; 40:397-409.
27. 17 peptides. Arthritis Rheum 1998; 41:1919-1929.
28. Frisbie DD, McIlwraith CW. Evaluation of gene therapy as a treatment for equine traumatic arthritis and osteoarthritis. Clin Orthop 2000; 379(Suppl):273-287.
29. Evans CH, Ghivizzani SC, Kang R, Muzzonigro T, Wasko MC, Herndon JH, Robbins PD. Gene therapy for rheumatoid diseases. Arthritis Rheum 1999; 42:1-16.
30. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989; 7:445-480.
31. Dickinson LA, Joh T, Kohwi Y, Kohwi-Shigematsu T. A tissue specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell 1992; 70:631-645.
32. Swain SL, Dialynas DP, Fitch FW, English M. Monoclonal antibody to L3T4 blocks the function of T cells specific for class 2 major histocompatibility complex antigens. J Immunol 1984; 132:1118-1123.
33. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994; 91:2762-2766.
34. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T-cell costimulation. Annu Rev Immunol 1996; 14:233-258.
35. Shahinian A, Pfeffer K, Lee KP, Kundig TM, Kishihara K, Wakeham A, Kawai K, Ohashi PS, Thompson CB, Mak TW. Differential T-cell costimulatory requirements in CD28-deficient mice. Science 1993; 261:609-612.
36. Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 1992; 176:1595-1604.
37. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, Singh C, Tepper MA. Immunosuppression in vivo by a soluble form of the CTLA4 T-cell activation molecule. Science 1992; 257:792-795.
38. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA-4 Ig. Science 1992; 257:789-792.
39. Lin H, Bolling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, Turka LA. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178:1801-1806.
40. Miossec P, van den Berg WB. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997; 40:2105-2115.
41. Joosten LA, Lubberts E, Durez P, Helsen MM, Jacobs MJ, Goldman M, van den Berg WB. Role of interleukine-4 and interleukin-10 in murine collagen-induced arthritis: protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40:249-260.
42. Persson S, Mikulowska A, Narula S, O'Garra A, Holmdahl R. Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats. Scand J Immunol 1996; 44:607-614.
43. Horsfall AC, Butler DM, Marinova L, Warden PJ, Williams RO, Maini RN, Feldmann M. Suppression of collagen-induced arthritis by continuous administration of IL-4. J Immunol 1997; 159:5687-5696.
44. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor. Arthritis Rheum 1993; 36:1618-1690.
45. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen-induced arthritis in mice is arrested by treatment with anti-tumor necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992; 77:510-514.
46. Williams RO, Feldmann M, Manini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89:9784-9788.
47. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151:6602-6607.
48. Drevlow B, Capezio, J, Lovis R, Jacobs C, Landay A, Pope RM. Phase I study of recombinant human interleukin-1 receptor (RHU IL-1R) administered intra-articularly in active rheumatoid arthritis. Arthritis Rheum 1993; 36(Suppl):S39.
49. Bresnihan B, Lookabaugh J, Wilt K, Musikic P. Treatment with recombinant human interleukin-1 receptor antagonist (rhIL-1ra) in rheumatoid arthritis (RA), Arthritis Rheum 1993; 36(Suppl):S73.
50. Miller-Ladner U, Roberts CR, Franklin BN, Gary RE, Robbins PD, Evans CH, Gay S. Gene transfer Human IL-IRa gene transfer into human synovial fibroblasts is chondroprotective. J Immunol 1997; 158:3492-3498.
51. Brinckerhoff CE, Auble DT. Regulation of collagenase gene expression in synovial fibroblasts. Ann N Y Acad Sci 1990; 580:355-374.
52. Barrett AJ. Introduction to the history and classification of proteases. In: Barrett AJ, editor. Proteases in Mammalian Cells and Tissues. Amsterdam: Elsevier, 1997: 1-55.
53. Cawston TE. Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol Ther 1996; 3:163-182.
54. Firestein GS, Paine MM. Stromelysin and tissue inhibitor of metalloproteinase gene expression in rheumatoid arthritis synovium. Am J Pathol 1992; 140:1309-1314.
55. Vincenti MP, Clark IM, Brinckerhoff, CE. Using inhibitors of metalloproteinase to treat arthritis. Easier said than done? Arthritis Rheum 1994; 37:1115-1126.
56. Carmichael DF, Stricklin GP, Stuart JM. Systemic administration of TIMP in the treatments of collagen-induced arthritis in mice. Agents Actions 1989; 27:378-379.
57. Ghivizzani SC, Oligino TJ, Glorioso JC, Robbins PD, Evans CH. Gene therapy approach for treating rheumatoid arthritis. Clin Orthop 2000; 379(Suppl):288-299.
58. Robbins PD, Tahara H, Ghivizzani SC. Viral vectors for gene therapy. Trends Biotechnol 1998; 19:35-40.
59. Nita I, Ghivizzani SC, Galea-Lauri J, Bandara G, Georgescu HI, Robbins PD, Evans CH. Direct gene delivery to synovium: An evaluation of potential vectors in vitro and in vivo. Arthritis Rheum 1996; 39:820-828.
60. Oligino T, Ghivizzani S, Wolfe D, Lechman E, Krisky D, Mi Z, Evans CC, Robbins P, Glorioso J. Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis. Gene Ther 1999; 6:1713-1720.
61. Pan RY, Xiao X, Chen SL, Li J, Lin LC, Wang HJ, Tsao YP. Disease-inducible transgene expression from a recombinant adeno-associated virus vector in a rat arthritis model. J Virol 1999; 73:3410-3417.
62. Quattrocchi E, Walmsley M, Browne K, Williams RO, Marinova-Mutafchieva L, Buurman W, Butler DM, Feldmann M. Paradoxical effects of adenovirus mediated blockade of TNF activity in murine collagen-induced arthritis. J Immunol 1999; 163:1000-1009.
63. Glorioso JC, Goins WF, Schmidt MC, Oligino T, Krisky DM, Marconi PC, Cavalcoli JD, Ramakrishnan R, Poliani PL, Fink DJ. Engineering herpes simplex virus vectors for human gene therapy. Adv Pharmacol 1997; 40:103-106.
64. Evans CH, Robbins PD. The promise of a new clinical trial: Intra-articular IL-1 receptor antagonist. Proc Assoc Am Physicians 1996; 108:1-5.
65. Evans CH, Robbins PD, Ghivizzani SC. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996; 7:1261-1280.
66. Ghivizzani SC, Oligino TJ, Glorioso, JC, Robbins PD, Evans CH. Direct gene delivery strategies for the treatment of rheumatoid arthritis. Drug Disc Today 2001; 6:259-267.
67. Oligino TC. Vector systems for gene transfer to joints. Clin Orthop 2000; 379(Suppl):17-30.
68. Bakker AC, Joosten LA, Arntz OJ, Helsen MM, Bendele AM, van de Loo, FA, van den Berg WB. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997; 40:893-900.
69. Le CH, Nicolson AG, Morales A, Sewell KL. Suppression of collagen-induced arthritis through adenovirus-mediated transfer of modified tumor necrosis factor alpha receptor gene. Arthritis Rheum 1997; 40:1662-1669.
70. Mageed RA, Adams G, Woodrow D, Podhajcer OL, Chernajovsky Y. Prevention of collagen-induced arthritis by gene delivery of soluble p75 tumor necrosis factor receptor. Gene Ther 1998; 5:1584-1592.
71. Ghivizzani SC, Lechman ER, Kang R, Tio C, Kolls J, Evans CH, Robbins PD. Direct adenovirus gene transfer of interleukin 1 and tumor necrosis factor-α soluble receptors to rabbit knees with arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci USA 1998; 95:4613-4618.
72. Song XY, Gu M, Jin WW, Klinman DM, Wahl SM. Plasmid DNA encoding transforming growth factor-β1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model. J Clin Invest 1998; 101:2615-2621.
73. Woods JM, Tokuhira M, Berry JC, Katschke KJ, Kurata H, Damergis JA. Interleukin-4 adenoviral gene therapy reduces production of inflammatory cytokines and prostaglandin E2 by rheumatoid arthritis synovium ex vivo. J Invest Med 1999; 47:285-292.
74. Kim SH, Evans CH, Kim S, Oligino T, Ghivizzani SC, Robbins PD. Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4. Arthritis Res 2000; 2:293-302.
75. La Cava A, Billetta R, Gaietta G, Bonnin DB, Baird SM, Albani S. Cell-mediated DNA transport between distant inflammatory sites following intradermal DNA immunization in the presence of adjuvant. J Immunol 2000; 164:1340-1345.
76. + T cells through IL-12 produced Listeria-induced macrophages. Science 1993; 260:547-549.
77. Aragane Y, Riemann H, Bhardwaji RS, Schwarz A, Sawada Y, Luger TA, Kubin M, Trinchieri G, Schwarz T. IL-12 is expressed and released by human keratinocytes and epidermoid carcinoma cell lines. J Immunol 1994; 153:5366-5372.